EN10 A gynecological cancer clinical trial

CCTG EN10 study is tailoring therapy for post-surgical patients with low-risk endometrial cancer

EN10 (RAINBO BLUE & TAPER) is a new Canadian clinical trial that is applying state-of-the-art molecular testing to classify post-surgery treatments in early-stage endometrial cancer to identify people at low risk of cancer recurrence based on the molecular features of their tumours.

More >>
 
Three trials funded GU ASCENDE, IND241 SURELY, EN11 RAINBO-GREEN

CIHR SUCCESS with 7.5 million for three trials: GU ASCENDE, IND241 SURELY, EN11 RAINBO-GREEN

Three CCTG trials were recently awarded nearly $7.5M from the Canadian Institutes of Health Research (CIHR) 2022 Spring Project Grant competition.

More >>
 
Expansion of the Tissue Bank facilities

Expansion of the Tissue Bank facilities

The recently launched Centre for Health Innovation, aims to connect researchers from across multiple disciplines to tackle the most pressing human health challenges. A critical part of the centre will be a new home for the CCTG Tumour Tissue Data Repository and includes a large-scale expansion of its histopathology and biobanking resources.

More >>
 

Matching ExCELLirate Canada funding from The Ontario Research Fund

It was recently announced that ExCELLirate Canada has successfully been granted a Research Infrastructure award of $4,159,049 by the Ontario Research Fund for the Innovation Fund Project Grant "ExCELLirate Canada: Expanding CELL-based Immunotherapy Research Acceleration for Translation and Evaluation".

More >>
 

Planned trials

AL6

MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML

ALC7

Master Screening and Reassessment Protocol (MYELOMATCH) for the NCI myeloMATCH clinical trials

ALC8

Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)

ALC9

Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)

CRC10

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

EN11

RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features. The MMRD-GREEN trial

More >>

GA4

Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

HD12

PET Response Adapted Design Comparing ABVD +/- ISRT with A2VD +/- ISRT in Patients with Stage IA/IIA Hodgkin Lymphoma (RADAR)

HN12

PembROlizumab with or without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma (PROMOTE-HN)

More >>

HN13

Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)

I242A

A Phase II Pre-operative Trial of JDQ433 in Surgically Resectable NSCLC

ME16

Adjuvant Treatment Guided by Response Post Neoadjuvant Therapy for Stage III Melanoma

NE1

NET RETREAT: 177Lutetium- DOTATATE Retreatment vs. Everolimus in Metastatic/unresectable Midgut NET

More >>

PR23

Evaluating the Impact of SBRT with or without Nirapariib in Metastatic Hormone Sensitive Prostate Cancer Treated with ADT and Androgen Axis Directed Therapy

PR24

Androgen Suppression combined with Elective Nodal and a Dose Escalated Boost. Stereotactic Body Radiation Therapy vs Brachytherapy Boost (ASCENDE-SBRT)

PR25

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes

SC28

The SEEMLESS Study: A randomized trial of a SmartphonE App-based MindfuLnEss intervention for cancer SurvivorS

VU2

STRatIfication of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision: STRIVE Study

Recently activated

BLC5

MAIN-CAV: Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum Based Chemotherapy in Metastatic Urothelial Cancer

More >>

EN10

Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)

More >>

HN11

SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)

More >>

I241

A Liquid-biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

More >>

I241A

Liquid-Biopsy Monitoring for Patients not yet Eligible for Screening and Enrollment

More >>

MA41

De-escalation of Chemo in HER-2+, ER-, Node-negative, breast cancer patients who achieved complete response after chemo and Dual HER-2 blOckade (DECRESCENDO)

More >>

Fighting a rare battle

Cancer is not a single disease; it is hundreds. Cancers of the lung, breast, prostate, and colon are the most common forms of the disease, and account for about half of all diagnoses. But less common forms of cancer also account for about half of diagnoses, and these are not as well studied.

More >>
 
The Impact of the COVID-19 on Canadians Living with Cancer

CCTG SC27 - The Impact of the COVID-19 on Canadians Living with Cancer

CCTG has launched a patient-centred observational study: SC27 Living With Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors. The aim of this study is to examine the emotional and physical consequences of living with cancer during this pandemic and the impact it may have on your quality of life and changes in your cancer care and follow-up.

More >>
 
Britton Smith Foundation Clinical Trials Fund

Donation helps advance research

The establishment of the Britton Smith Foundation Clinical Trials Fund.  A thank you from Doug Kane, senior manager, Canadian Cancer Society FLA & The Waterways Community Office.

More >>
 

Asking the right questions

Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.  

“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”

More >>
 

Publications

Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients

Translational Lung Cancer Research 10: 826 - 838, 21 F
Fung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;

More >>

Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial (ONLINE)

J Clin Oncol , 2023
Speers CW;Symmans WF;Barlow WE;Trevarton A;The S;Du L;Rae JM;Shak S;Baehner R;Sharma P;Pusztai L;Hortobagyi GN;Hayes DF;Albain KS;Godwin A;Thompson A;

More >>

Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results

J Clin Oncol 41: 233 - 242, 2023
Kennecke HF;O'Callaghan CJ;Loree JM;Moloo H;Auer R;Jonker DJ;Raval M;Musselman R;Ma G;Caycedo-Marulanda A;Simianu VV;Patel S;Pitre LD;Helewa R;Gordon VL;Neumann K;Nimeiri H;Sherry M;Tu D;Brown CJ;

More >>

Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)

J Clin Oncol 41: 243 - 254, 2023
Brown JC;Ma C;Shi Q;Fuchs CS;Meyer J;Niedzwiecki D;Zemla T;Couture F;Kuebler P;Kumar P;Lewis D;Tan B;Krishnamurthi S;O'Reilly EM;Shields AF;Meyerhardt JA;

More >>

Evaluating the time toxicity of cancer treatment in the CCTG CO.17 randomized clinical trial (RCT)

J Clin Oncol 40: 248 - 248, 2022
Gupta A;O'Callaghan CJ;Zhu L;Jonker DJ;Wong R;Colwell B;Moore MJ;Karapetis CS;Tebbutt NC;Shapiro JD;Tu D;Booth CM;

More >>

Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials (ONLINE)

J Clin Oncol , 2022
Pagani O;Walley BA;Fleming GF;Colleoni M;Lang I;Gomez HL;Tondini C;Burstein HJ;Goetz MP;Ciruelos EM;Stearns V;Bonnefoi HR;Martino S;Geyer CE;Chini C;Puglisi F;Spazzapan S;Ruhstaller T;Winer EP;Ruepp B;Loi S;Coates AS;Gelber RD;Goldhirsch A;Regan MM;Francis PA;

More >>

Reproductive Outcomes in Young Breast Cancer Survivors Treated (15–39) in Ontario, Canada

Current Oncology 29: 8591 - 8599, 2022
Rushton M;Pudwell J;Wei X;Powell M;Richardson H;Velez MP;

More >>